Please try another search
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Gwen A. Melincoff | 70 | 2017 | Independent Director |
Rita J. Balice-Gordon | 61 | 2020 | Independent Director |
Neil F. McFarlane | 49 | 2022 | Independent Director |
Michael Thomas Heffernan | 60 | 2002 | Co-Founder, Chairman, Interim CEO & President |
Cynthia G. McCormick | - | - | Scientific Advisor |
William T. Zempsky | - | - | Scientific Advisor |
Gino Santini | 67 | 2012 | Lead Independent Director |
Srinivas Nalamachu | - | - | Scientific Advisor |
Richard L. Rauck | - | - | Scientific Advisor |
Charles E. Argoff | - | - | Scientific Advisor |
Robert H. Dworkin | - | - | Scientific Advisor |
Lynn R. Webster | - | - | Scientific Advisor |
Garen G. Bohlin | 77 | 2015 | Independent Director |
Nathaniel P. Katz | - | - | Scientific Advisor |
John Gordon Freund | 70 | 2014 | Independent Director |
Joseph V. Pergolizzi | 54 | - | Scientific Advisor |
Bill McCarberg | - | - | Scientific Advisor |
John A. Fallon | 76 | 2016 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review